Dr Ludovic Vallier

Ludovic uses human pluripotent stem cells - cells with the ability to develop into almost any type of cell in the body - to study how biological mechanisms direct them to become a pancreas or liver cell. He is also investigating the role these mechanisms play in diabetes and other metabolic disorders.

Ludovic graduated in Molecular biology and Immunology from the University Claude Bernard Lyon I in 1997.

In 2001, he earned his PhD at Ecole Normale Superieur of Lyon in the group of Jacques Samarut, under the supervision of Pierre Savatier, studying mechanisms that control the cell cycle in mouse embryonic stem (ES) cells.

Following a year in the biotechnology industry, Ludovic joined Professor Pedersen's group at the University of Cambridge Department of Surgery to work on human ES cells and the mechanisms controlling their differentiation into endodermal cells (cells which make up the gastrointestinal tract and related organs such as the liver and pancreas). In 2005, he was awarded a stem cells career development fellowship jointly funded by the Medical Research Council (MRC) and Diabetes UK to study the molecular mechanisms that induce human pluripotent stem cells to become pancreas cells.

After this, he was awarded a MRC senior-non clinical fellowship in 2008 to further develop his interest on endoderm differentiation toward liver and pancreas and joined the newly opened Anne McLaren Laboratory for Regenerative Medicine (LRM) as a Principal Investigator. Since, he has been studying the molecular mechanisms controlling early cell fate decisions and used this knowledge to develop laboratory-based systems for modelling metabolic disorders.

Ludovic is now Reader in Stem Cells and Regenerative Medicine and member of the Cambridge Stem Cell Institute. He is also the director of the Cambridge National Institute for Health Research (NIHR)/Biomedical Research Centre HiPSC (human induced pluripotent stem cell) core facility.

Ludovic joined the Sanger Institute in 2012 as a member of Faculty with a joint appointment with Cambridge University. His is studying the genetic mechanisms that control pancreas and liver development to uncover new targets for treating metabolic disorders such as diabetes.

Selected Publications

  • TEAD and YAP regulate the enhancer network of human embryonic pancreatic progenitors.

    Cebola I, Rodríguez-Seguí SA, Cho CH, Bessa J, Rovira M, Luengo M, Chhatriwala M, Berry A, Ponsa-Cobas J, Maestro MA, Jennings RE, Pasquali L, Morán I, Castro N, Hanley NA, Gomez-Skarmeta JL, Vallier L and Ferrer J

    Nature cell biology 2015;17;5;615-26

  • Activin/nodal signaling and NANOG orchestrate human embryonic stem cell fate decisions by controlling the H3K4me3 chromatin mark.

    Bertero A, Madrigal P, Galli A, Hubner NC, Moreno I, Burks D, Brown S, Pedersen RA, Gaffney D, Mendjan S, Pauklin S and Vallier L

    Genes & development 2015;29;7;702-17

  • Genetic background drives transcriptional variation in human induced pluripotent stem cells.

    Rouhani F, Kumasaka N, de Brito MC, Bradley A, Vallier L and Gaffney D

    PLoS genetics 2014;10;6;e1004432

  • The cell-cycle state of stem cells determines cell fate propensity.

    Pauklin S and Vallier L

    Cell 2013;155;1;135-47

  • Generation of multipotent foregut stem cells from human pluripotent stem cells.

    Hannan NR, Fordham RP, Syed YA, Moignard V, Berry A, Bautista R, Hanley NA, Jensen KB and Vallier L

    Stem cell reports 2013;1;4;293-306

  • Inhibition of activin/nodal signalling is necessary for pancreatic differentiation of human pluripotent stem cells.

    Cho CH, Hannan NR, Docherty FM, Docherty HM, Joåo Lima M, Trotter MW, Docherty K and Vallier L

    Diabetologia 2012;55;12;3284-95

  • Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells.

    Yusa K, Rashid ST, Strick-Marchand H, Varela I, Liu PQ, Paschon DE, Miranda E, Ordóñez A, Hannan NR, Rouhani FJ, Darche S, Alexander G, Marciniak SJ, Fusaki N, Hasegawa M, Holmes MC, Di Santo JP, Lomas DA, Bradley A and Vallier L

    Nature 2011;478;7369;391-4

  • Activin/Nodal signaling controls divergent transcriptional networks in human embryonic stem cells and in endoderm progenitors.

    Brown S, Teo A, Pauklin S, Hannan N, Cho CH, Lim B, Vardy L, Dunn NR, Trotter M, Pedersen R and Vallier L

    Stem cells (Dayton, Ohio) 2011;29;8;1176-85

  • Pluripotency factors regulate definitive endoderm specification through eomesodermin.

    Teo AK, Arnold SJ, Trotter MW, Brown S, Ang LT, Chng Z, Robertson EJ, Dunn NR and Vallier L

    Genes & development 2011;25;3;238-50

  • Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells.

    Rashid ST, Corbineau S, Hannan N, Marciniak SJ, Miranda E, Alexander G, Huang-Doran I, Griffin J, Ahrlund-Richter L, Skepper J, Semple R, Weber A, Lomas DA and Vallier L

    The Journal of clinical investigation 2010;120;9;3127-36

  • Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development.

    Touboul T, Hannan NR, Corbineau S, Martinez A, Martinet C, Branchereau S, Mainot S, Strick-Marchand H, Pedersen R, Di Santo J, Weber A and Vallier L

    Hepatology (Baltimore, Md.) 2010;51;5;1754-65

  • SIP1 mediates cell-fate decisions between neuroectoderm and mesendoderm in human pluripotent stem cells.

    Chng Z, Teo A, Pedersen RA and Vallier L

    Cell stem cell 2010;6;1;59-70

* quick link - http://q.sanger.ac.uk/rmext83j